← Leaderboards
William K Plunkett
University Of Texas Md Anderson Can Ctr
$8,981,153
Attributed
$9,458,175
Total exposure
12
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $916.7K · FY2005–22$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$9,458,175 · 12
By mechanism
R01$5,475,465 · 3
P01$2,400,513 · 5
P50$1,501,945 · 3
P30$80,252 · 1
Top collaborators
- William George Wierda3 shared
Others in their field
Top investigators on “Nucleoside Analog”
- Constance Ann Benson · University Of California, San Diego$84,289,569
- Robert Turner Schooley · University Of Colorado Denver$49,550,018
- Jeffrey S Glenn · Stanford University$19,514,752
- Ruth Martha Greenblatt · University Of California San Francisco$19,382,210
- Vern L. Schramm · Yeshiva University$18,631,228
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
Research focus
Nucleoside AnalogCellsResponseBaseInvestigationClinical TrialsPharmaceutical PreparationsResistanceDna RepairDesignRepairedPathway InteractionsKillingsLaboratoriesDna DamageClinical ResearchNeoplasm /Cancer PharmacologyLeukemiaAnalogMutationIn VitroBiological ModelsLesionRefractory
Grant awards (57)
Developmental Research Program$69,629
P50 · FY2022 · CA · contact PI
15 Developmental Therapeutics$18,707
P30 · FY2022 · CA · contact PI
Developmental Research Program$69,630
P50 · FY2021 · CA · contact PI
15 Developmental Therapeutics$18,707
P30 · FY2021 · CA · contact PI
Developmental Research Program$95,969
P50 · FY2020 · CA · contact PI
15 Developmental Therapeutics$18,676
P30 · FY2020 · CA · contact PI
Developmental Research Program$69,630
P50 · FY2019 · CA · contact PI
15 Developmental Therapeutics$18,707
P30 · FY2019 · CA · contact PI
15 Developmental Therapeutics$5,455
P30 · FY2019 · CA · contact PI
Developmental Research Program$20,190
P50 · FY2018 · CA · contact PI
Mechanism-Based Pharmacologic Intervention$118,119
P01 · FY2016 · CA · contact PI
Biochemical Basis for Therapeutic Activity$249,063
R01 · FY2015 · CA · contact PI
Mechanism-Based Pharmacologic Intervention$144,879
P01 · FY2015 · CA · contact PI
Sapacitabine therapy to create synthetic lethality in DNA repair-deficient CLL$318,015
R01 · FY2014 · CA
Biochemical Basis for Therapeutic Activity$241,591
R01 · FY2014 · CA · contact PI
Mechanism-Based Pharmacologic Intervention$143,443
P01 · FY2014 · CA · contact PI
Sapacitabine therapy to create synthetic lethality in DNA repair-deficient CLL$308,179
R01 · FY2013 · CA
Biochemical Basis for Therapeutic Activity$234,119
R01 · FY2013 · CA · contact PI
Mechanism-Based Pharmacologic Intervention$124,641
P01 · FY2013 · CA · contact PI
Developmental Research Program$86,998
P50 · FY2013 · CA · contact PI
Sapacitabine therapy to create synthetic lethality in DNA repair-deficient CLL$327,850
R01 · FY2012 · CA
Biochemical Basis for Therapeutic Activity$249,063
R01 · FY2012 · CA · contact PI
Development of Sapacitabine Therapy in Leukemias$188,182
P50 · FY2012 · CA · contact PI
Mechanism-Based Pharmacologic Intervention$151,641
P01 · FY2012 · CA · contact PI
Biochemical Basis for Therapeutic Activity$249,063
R01 · FY2011 · CA · contact PI
Development of Sapacitabine Therapy in Leukemias$237,113
P50 · FY2011 · CA · contact PI
Development of Mechanism-Based Stratgies for CLL Therapy$270,252
P01 · FY2010 · CA · contact PI
Development of Sapacitabine Therapy in Leukemias$234,723
P50 · FY2010 · CA · contact PI
Development of Mechanism-Based Stratgies for CLL Therapy$266,004
P01 · FY2009 · CA · contact PI
Development of Sapacitabine Therapy in Leukemias$256,449
P50 · FY2009 · CA · contact PI
Development of Mechanism-Based Stratgies for CLL Therapy$252,101
P01 · FY2008 · CA · contact PI
Biochemical Basis for Therapeutic Activity$238,029
R01 · FY2008 · CA · contact PI
Development of Sapacitabine Therapy in Leukemias$173,432
P50 · FY2008 · CA · contact PI
Development of Mechanism-Based Stratgies for CLL Therapy$250,694
P01 · FY2007 · CA · contact PI
Biochemical Basis for Therapeutic Activity$238,029
R01 · FY2007 · CA · contact PI
Biochemical Basis for Therapeutic Activity$245,138
R01 · FY2006 · CA · contact PI
Cellular Pharmacology in Cancer Chemotherapy$243,515
R01 · FY2006 · CA · contact PI
Development of Mechanism-Based Stratgies for CLL Therapy$184,805
P01 · FY2006 · CA · contact PI
Biochemical Basis for Therapeutic Activity$251,038
R01 · FY2005 · CA
Cellular Pharmacology in Cancer Chemotherapy$249,375
R01 · FY2005 · CA
Biochemical Basis for Therapeutic Activity$251,038
R01 · FY2004 · CA
Cellular Pharmacology in Cancer Chemotherapy$249,375
R01 · FY2004 · CA
Cellular Pharmacology in Cancer Chemotherapy$249,375
R01 · FY2003 · CA
Cellular Pharmacology in Cancer Chemotherapy$249,375
R01 · FY2002 · CA
BIOCHEMICAL BASIS FOR THERAPEUTIC ACTIVITY$203,619
R01 · FY2002 · CA
Novel pharmacologic agents in CLL$165,355
P01 · FY2002 · CA
OVERCOMING RESISTANCE TO THERAPEUTIC NUCLEOSIDE ANALOGS$0
P01 · FY2002 · CA
BIOCHEMICAL BASIS FOR THERAPEUTIC ACTIVITY$199,112
R01 · FY2001 · CA
Novel pharmacologic agents in CLL$165,355
P01 · FY2001 · CA
OVERCOMING RESISTANCE TO THERAPEUTIC NUCLEOSIDE ANALOGS$0
P01 · FY2001 · CA
Novel pharmacologic agents in CLL$0
P01 · FY2001 · CA
Novel pharmacologic agents in CLL$0
P01 · FY2001 · CA
PHARMACOKINETICS AND PHARMACODYNAMICS IN ACUTE MYELOGENOUS LEUKEMIA$0
P01 · FY2001 · CA
CELLULAR PHARMACOLOGY IN CANCER CHEMOTHERAPY$236,769
R01 · FY2000 · CA
BIOCHEMICAL BASIS FOR THERAPEUTIC ACTIVITY$194,735
R01 · FY2000 · CA
PHARMACOKINETICS AND PHARMACODYNAMICS IN ACUTE MYELOGENOUS LEUKEMIA$163,224
P01 · FY2000 · CA
Novel pharmacologic agents in CLL$0
P01 · FY2000 · CA